Answers are grounded in this paper and cite their sources.
Triple-negative breast cancer (TNBC) lacks therapeutic targets and has poor prognosis, creating a need for new molecular targets. We combined bioinformatics analysis of TNBC datasets with experimental validation. Techniques included gain- and loss-of-function studies, autophagy and ferroptosis assays, co-immunoprecipitation, and ubiquitination analysis. A ZIF-8-based nanoplatform co-loaded with UCHL5-IN-1 and 1,6-HD was developed and tested in vitro and in vivo. UCHL5 was overexpressed in TNBC and linked to poor survival. UCHL5 deubiquitinated and stabilized ALK5, promoting its liquid-liquid phase separation (LLPS). ALK5 condensates activated the ALK5–SMAD2/3–GPX4 axis, suppressing both autophagy and ferroptosis to drive tumor progression. Inhibiting UCHL5 disrupted this axis, restored autophagy–ferroptosis crosstalk, and inhibited tumor growth. The ZIF-8@1,6-HD@UCHL5-IN-1 nanoplatform targeted this pathway, induced ferroptosis, and suppressed TNBC growth safely in vivo. We identify a UCHL5–ALK5–LLPS axis that confers ferroptosis resistance in TNBC. Targeting this axis with a designed nanoplatform represents a promising dual-pathway therapeutic strategy against treatment resistance.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: